CA
NZ
UK
AU
IND
US
…
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on LB Pharmaceuticals Inc (LBRX) is scarce; the company is listed on NASDAQ and appears to be a pharmaceutical/biotechnology firm focused on developing therapeutic products. Its long-term growth may depend on progress in clinical development, regulatory approvals, licensing or commercialization partnerships, and access to financing, which could make it attractive to investors seeking exposure to early-stage drug developers.
Key investment risks include binary clinical and regulatory outcomes, an uncertain operating history and low liquidity, heavy reliance on external financing or partners, and potential shareholder dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -25.20M | -63.10M | -6.27M | -14.35M |
| Net income | -25.20M | -63.10M | -6.28M | -14.35M |
| Selling general administrative | 13.66M | 13.66M | 3.53M | 1.46M |
| Gross profit | -0.32M | - | - | - |
| Reconciled depreciation | 0.32M | 0.09M | 0.00M | 0.00M |
| Ebit | -25.20M | -63.10M | -1.45M | -12.20M |
| Ebitda | -24.88M | -63.01M | -1.45M | -12.19M |
| Depreciation and amortization | 0.32M | 0.09M | 0.00M | 0.00M |
| Operating income | -30.40M | -64.83M | -11.38M | -2.81M |
| Other operating expenses | 30.40M | 64.83M | 11.38M | 2.81M |
| Interest expense | - | 0.00M | 4.83M | 2.15M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 3.92M | 1.72M | 0.81M | 0.07M |
| Net interest income | 3.92M | 1.72M | -4.01M | -2.08M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 30.40M | 64.83M | 11.38M | 2.81M |
| Cost of revenue | 0.32M | - | - | - |
| Total other income expense net | 5.20M | 1.73M | 5.10M | -11.54M |
| Net income from continuing ops | -25.20M | -63.10M | -6.28M | -14.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 312.93M | 33.53M | 45.66M | 21.49M |
| Other current assets | 13.22M | 0.88M | 2.34M | 0.09M |
| Total liab | 11.62M | 128.09M | 80.13M | 50.30M |
| Total stockholder equity | 301.31M | -94.55M | -34.47M | -28.81M |
| Other current liab | 4.58M | 5.30M | 1.22M | 0.31M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -129.53M | -104.32M | -41.22M | -34.95M |
| Cash | 250.17M | 22.98M | 14.98M | 21.40M |
| Total current liabilities | 7.44M | 8.11M | 2.61M | 0.47M |
| Net debt | -246.60M | -19.27M | -14.98M | 2.74M |
| Short term debt | 0.73M | 0.49M | - | - |
| Short long term debt total | 3.57M | 3.70M | - | 24.15M |
| Other stockholder equity | 430.67M | 9.66M | 6.47M | 6.13M |
| Total current assets | 308.43M | 28.88M | 45.63M | 21.49M |
| Short term investments | 45.04M | 5.02M | 28.31M | 0.00M |
| Long term debt | - | - | - | 24.15M |
| Accounts payable | 2.13M | 2.32M | 1.39M | 0.16M |
| Accumulated other comprehensive income | 0.17M | 0.11M | 0.27M | - |
| Non currrent assets other | 0.77M | 0.50M | - | - |
| Non current assets total | 4.50M | 4.66M | 0.02M | 0.00M |
| Capital lease obligations | 3.57M | 3.70M | 0.00M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | -39.84M | 23.23M | -28.01M | 0.12M |
| Total cashflows from investing activities | -39.89M | 23.23M | -28.01M | 0.12M |
| Net borrowings | - | 0.00M | 0.72M | 25.00M |
| Total cash from financing activities | 302.56M | 38.31M | 33.68M | 22.96M |
| Net income | -25.20M | -63.10M | -6.28M | -14.35M |
| Change in cash | 227.19M | 8.50M | -6.42M | 20.36M |
| Begin period cash flow | 22.98M | 14.98M | 21.40M | 1.05M |
| End period cash flow | 250.17M | 23.48M | 14.98M | 21.40M |
| Total cash from operating activities | -35.21M | -53.05M | -12.09M | -2.73M |
| Issuance of capital stock | 327.75M | 40.00M | 35.00M | 0.90M |
| Depreciation | 0.32M | 0.09M | 0.00M | 0.00M |
| Change to account receivables | -0.27M | 0.11M | -0.15M | - |
| Other cashflows from financing activities | - | 38.31M | 32.95M | -2.04M |
| Capital expenditures | 0.05M | 0.77M | 0.03M | 0.00M |
| Change in working capital | -13.65M | 3.31M | -1.31M | 0.09M |
| Stock based compensation | 4.19M | 3.16M | 0.29M | 0.43M |
| Other non cash items | 3.33M | 3.48M | -4.80M | 11.10M |
| Free cash flow | -35.26M | -53.82M | -12.12M | -2.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals Inc Common Stock |
- -% |
39.70 | - | - | - | 4.35 |
| NVO Novo Nordisk A/S |
0.29 0.72% |
40.29 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
5.51 0.99% |
564.39 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
34.06 3.67% |
961.95 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Ms. Heather D. Turner Esq., J.D. | CEO & Director | 1973 |
| Mr. Gad Soffer | Chief Operating & Business Officer | 1977 |
| Dr. Anna Eramo M.D. | Advisor | 1975 |
| Mr. Joseph M. Miller C.P.A. | Chief Financial Officer | 1974 |
| Ms. Minako Pazdera J.D., Ph.D. | General Counsel | NA |
| Ms. Lindsay Beaupre | Senior VP of People & Culture | NA |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations | 1968 |
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs | NA |
| Ms. Ellen Rose | Senior Vice President of Corporate Affairs | NA |
| Ms. Kaya Pai Panandiker Kamlesh | Chief Commercial Officer | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.80%
Communication Services
+0.61%
Consumer Cyclical
+1.47%
Consumer Defensive
+0.78%
Energy
-1.20%
Financial Services
+0.87%
Financials
+0.88%
Healthcare
-0.33%
Industrials
+0.85%
Real Estate
+0.50%
Technology
+0.39%
Utilities
+0.03%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...